NEW YORK (360Dx) – Oxford Immunotec today said that it plans to sell 2.5 million shares of its ordinary shares to investment bank BTIG to raise $40.1 million in gross proceeds. 

The diagnostic firm announced its plans to sell the shares after the close of the market on Monday and priced the sale today. It did not disclose the price of the shares. Oxford said it has granted BTIG the option to purchase up to an additional 375,000 shares. Net proceeds from the offering will be used for working capital and general corporate purposes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.